Trials / Unknown
UnknownNCT04522037
Measurement of the Efficacy of MORPHINE in the Early Management of Dyspnea in COVID-19 Positive Patients
Retrospective Study of the Measurement of the Efficacy of MORPHINE in the Early Management of Dyspnea in COVID-19 Positive Patients With Moderate to Severe Impairment Without Objective of Resuscitation Management (Level of Care 3 and 4) at the Hospices Civils of Lyon
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Hospices Civils de Lyon · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Morphine is used in the treatment of dyspnea and polypnea with a proven benefit on the improvement of these symptoms, both etiologically and symptomatically. This medication is used in particular in palliative care for this type of symptom. The Sars CoV2 viral pneumonia table can lead to respiratory distress. In patients with moderate to severe impairment without goal of resuscitation (level of care 3 and 4), the introduction of morphine may sometimes be necessary to relieve respiratory symptoms. These also lead to major exhaustion which can worsen the clinical picture. However, the prescription of morphine is not systematic in front of a respiratory distress table. The investigators hypothesized that early treatment with morphine lead to a better management of dyspnea, quality of live and survival in COVID-19 positive participants patients when there is not resuscitation objective management (level of care 3 and 4). The objective is to measure the efficacy of morphine in the early management of dyspnea, quality of life and survival in COVID-19 positive participants patients treated in the Hospices Civils of Lyon during COVID-19 pandemic.
Conditions
- Patients Hospitalized in the Hospices Civils of Lyon
- COVID-19 Disease
- Moderate to Severe Dyspnea
- Without Resuscitation Objective Management
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No intervention / Compare the difference in respiratory rate between H0 and H12 of the initiation of morphine between the control and interventional groups | Respiratory rate is analyzed with the scope (approved by the French national medical authorities) |
Timeline
- Start date
- 2020-06-01
- Primary completion
- 2020-09-01
- Completion
- 2021-02-01
- First posted
- 2020-08-21
- Last updated
- 2020-08-21
Locations
3 sites across 1 country: France
Source: ClinicalTrials.gov record NCT04522037. Inclusion in this directory is not an endorsement.